New Pill Rivals Ozempic With 16% Weight Loss

A daily pill just posted weight-loss numbers that rival the blockbuster injections millions of Americans already inject into their stomachs and thighs.

Story Snapshot

Aleniglipron, an oral GLP-1 drug from Structure Therapeutics, cut body weight by up to 11.3% versus placebo at 36 weeks in a phase 2b trial.
A related study, ACCESS II, showed even bigger drops, up to 16.3% placebo-adjusted weight loss at 44 weeks on higher doses.
Results were published in Nature Medicine and match or beat other oral GLP-1 pills now in development, including Eli Lilly’s orforglipron.
The drug still faces a phase 3 trial and Food and Drug Administration review before it could reach pharmacy shelves.

What The Trial Actually Found

Structure Therapeutics tested aleniglipron in adults with obesity or who were overweight, giving them daily doses of 45, 90, or 120 milligrams for 36 weeks. Every dose beat placebo by a wide margin. The 120-milligram group lost 11.3% more weight than the placebo group, a result with a p-value under 0.0001, meaning the odds this happened by chance are essentially zero.

The lower doses still performed well. The 45-milligram arm produced an 8.2% placebo-adjusted loss, and the 90-milligram arm hit 9.8%. Investigators tracked participants closely for 36 straight weeks, watching for side effects while measuring pounds lost. That kind of dose-response pattern, where more drug means more weight loss, gives researchers confidence the effect is real and not a fluke of one specific dosage.

A Separate Study Pushed The Numbers Higher

A companion trial called ACCESS II ran longer, 44 weeks, and used higher doses of 180 and 240 milligrams. Those participants lost even more weight. The placebo-adjusted figure hit 16.3%, or about 39 pounds, on the 180-milligram dose, and 16.0%, about 37 pounds, on the 240-milligram dose. Total weight loss, not adjusted against placebo, reached roughly 14.7% at the top studied dose in the earlier trial, putting aleniglipron near the upper edge of what any oral obesity drug has shown so far.

Where This Fits Among Rival Pills

Aleniglipron is not the only oral GLP-1 racing toward approval. Eli Lilly’s orforglipron delivered 12.4% weight loss in a 72-week phase 3 trial, though that came with a longer timeline than aleniglipron’s 36-week readout. Oral semaglutide, tested in the OASIS-4 trial, produced 13.6% weight loss over 64 weeks, performing similarly to its injectable version. Another competitor, CX11 from Corxel Pharmaceuticals, hit 11.5% at 36 weeks. Aleniglipron’s numbers stand up well against all three.

Every drug in this class shares the same trade-off. Nausea, vomiting, and other stomach-related side effects show up consistently across GLP-1 pills and injections alike. Structure Therapeutics reported discontinuation rates tied to side effects in the low single digits during extended follow-up, a signal the drug is tolerable enough for most patients to stick with it. That matters because a weight-loss drug only works if people can actually keep taking it.

Why A Pill Changes The Math For Patients

Injectable GLP-1 drugs like Ozempic and Wegovy already reshaped obesity treatment, but needles, refrigeration, and injector pens create real barriers for everyday people. A pill removes those obstacles. It travels easier, costs less to manufacture, and skips the needle anxiety that keeps some patients from starting treatment at all. For a health system already straining under obesity-related costs, a cheaper, simpler oral option is worth taking seriously rather than dismissing as hype.

Market watchers are paying attention too. Structure Therapeutics reportedly holds roughly 1.5 billion dollars in cash, enough runway to fund operations through 2028, and the company has signaled plans to start a phase 3 trial of aleniglipron by the third quarter of this year. That timeline puts a potential approval decision years away still, since phase 3 trials typically run longer and involve far more patients than the phase 2b study just published.

An experimental GLP-1 pill helped people with obesity or overweight lose as much as 12.1% of their body weight in just 36 weeks. Unlike injectable drugs such as Wegovy and Ozempic, aleniglipron is a small molecule that can be taken once daily with or withohttps://t.co/rlYsBFVMFY

— Michael W. Deem (@Michael_W_Deem) August 10, 2026

The Road Ahead Before Approval

Nothing here is final. Phase 2 results, even strong ones, do not guarantee phase 3 success, and obesity drug history includes plenty of promising mid-stage data that faded under larger trials. Regulators will also want longer safety data beyond 36 or 44 weeks before clearing a daily pill for widespread use. Patients and doctors watching this space should treat aleniglipron as a genuinely promising candidate, not yet a settled alternative to the injectables already on pharmacy shelves.